CN103946231A - 齐墩果酸酰胺化衍生物、及其制备方法和应用 - Google Patents

齐墩果酸酰胺化衍生物、及其制备方法和应用 Download PDF

Info

Publication number
CN103946231A
CN103946231A CN201280056912.XA CN201280056912A CN103946231A CN 103946231 A CN103946231 A CN 103946231A CN 201280056912 A CN201280056912 A CN 201280056912A CN 103946231 A CN103946231 A CN 103946231A
Authority
CN
China
Prior art keywords
oleanolic acid
pharmaceutically acceptable
acceptable salt
amidated derivative
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201280056912.XA
Other languages
English (en)
Other versions
CN103946231B (zh
Inventor
荣风光
徐荣臻
谢福文
赖洪喜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bunsen Pharmaceutical (Shanghai) Co., Ltd.
Original Assignee
Hangzhou Bensheng Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Bensheng Pharmaceutical Co Ltd filed Critical Hangzhou Bensheng Pharmaceutical Co Ltd
Publication of CN103946231A publication Critical patent/CN103946231A/zh
Application granted granted Critical
Publication of CN103946231B publication Critical patent/CN103946231B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/74—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/54—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

本发明属于天然药物及药物化学领域，具体涉及通式I的新型齐墩果酸酰胺化衍生物或其药学上可接受的盐，制备这些化合物的方法、包含该化合物的药物组合物及其在制备抗肿瘤药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201280056912.XA 2011-12-01 2012-11-30 齐墩果酸酰胺化衍生物、及其制备方法和应用 Active CN103946231B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2011083295 2011-12-01
CNPCT/CN2011/083295 2011-12-01
PCT/CN2012/085671 WO2013079024A1 (zh) 2011-12-01 2012-11-30 齐墩果酸酰胺化衍生物、及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN103946231A true CN103946231A (zh) 2014-07-23
CN103946231B CN103946231B (zh) 2016-10-26

Family

ID=48534683

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280056912.XA Active CN103946231B (zh) 2011-12-01 2012-11-30 齐墩果酸酰胺化衍生物、及其制备方法和应用

Country Status (6)

Country Link
US (1) US8987502B2 (zh)
EP (1) EP2787002B1 (zh)
JP (1) JP6043361B2 (zh)
CN (1) CN103946231B (zh)
DK (1) DK2787002T3 (zh)
WO (1) WO2013079024A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987502B2 (en) 2011-12-01 2015-03-24 Hangzhou Bensheng Pharmaceutical Co., Ltd. Oleanolic acid amidate derivatives, preparation methods and uses thereof
CN104861028A (zh) * 2014-02-24 2015-08-26 上海兰蒂斯生物医药科技有限公司 新型熊果酸衍生物、其制备方法及其应用
CN104861027A (zh) * 2014-02-24 2015-08-26 上海兰蒂斯生物医药科技有限公司 新型齐墩果酸衍生物、其制备方法及其应用
JP2015168633A (ja) * 2014-03-05 2015-09-28 東レ・ファインケミカル株式会社 安息香酸類の製造方法
CN105566435B (zh) * 2014-10-11 2017-12-19 中国科学院上海有机化学研究所 一种齐墩果酸衍生物及其制备方法和用途
US11584775B2 (en) 2015-09-23 2023-02-21 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses
EP3681477A4 (en) 2017-09-14 2021-06-09 Phoenix Biotechnology, Inc. IMPROVED METHOD AND COMPOSITION FOR THE TREATMENT OF CONDITIONS, DISEASES OR DISORDERS SENSITIVE TO TRITERPENES
RU2020113341A (ru) 2017-09-14 2021-10-15 Феникс Байотекнолоджи, Инк. Способ и композиция для лечения вирусной инфекции
EP4295854A3 (en) 2020-03-31 2024-04-03 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
KR102464428B1 (ko) 2020-03-31 2022-11-04 피닉스 바이오테크놀러지 인코포레이티드. 코로나바이러스 감염 치료를 위한 방법 및 조성물
CN113372406A (zh) * 2021-06-09 2021-09-10 山东大学 一种齐墩果酸衍生物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101367861A (zh) * 2007-08-15 2009-02-18 中国药科大学 2-羟基-3-脱氧五环三萜类化合物及其衍生物、其制备方法及用途
WO2009146216A2 (en) * 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CN102050861A (zh) * 2009-11-10 2011-05-11 中国药科大学 13(18)-烯齐墩果烷型五环三萜及其衍生物的制备
CN102083442A (zh) * 2008-04-18 2011-06-01 里亚塔医药公司 抗氧化剂炎症调节剂：在c-17具有氨基和其它修饰的齐墩果酸衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1164609C (zh) 2002-10-24 2004-09-01 青岛海洋大学 一种齐墩果酸乳糖缀合物及其制备方法和用途
CN1715291A (zh) * 2004-06-28 2006-01-04 田振坤 齐墩果酸丁二酸单酯的合成及其治疗急慢性肝炎药物制剂
CN102133219A (zh) 2010-09-27 2011-07-27 林秀坤 齐墩果酸的抗***作用及其药物制剂
CN102151275A (zh) 2010-11-07 2011-08-17 林秀坤 齐墩果酸的抗胰腺癌作用及其药物制剂
CN102070697A (zh) 2010-12-09 2011-05-25 中国药科大学 一种齐墩果酸衍生物、其制备方法及用途
US8987502B2 (en) 2011-12-01 2015-03-24 Hangzhou Bensheng Pharmaceutical Co., Ltd. Oleanolic acid amidate derivatives, preparation methods and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101367861A (zh) * 2007-08-15 2009-02-18 中国药科大学 2-羟基-3-脱氧五环三萜类化合物及其衍生物、其制备方法及用途
WO2009146216A2 (en) * 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CN102083442A (zh) * 2008-04-18 2011-06-01 里亚塔医药公司 抗氧化剂炎症调节剂：在c-17具有氨基和其它修饰的齐墩果酸衍生物
CN102050861A (zh) * 2009-11-10 2011-05-11 中国药科大学 13(18)-烯齐墩果烷型五环三萜及其衍生物的制备

Also Published As

Publication number Publication date
EP2787002A1 (en) 2014-10-08
JP2014534269A (ja) 2014-12-18
WO2013079024A1 (zh) 2013-06-06
US20140343108A1 (en) 2014-11-20
US8987502B2 (en) 2015-03-24
JP6043361B2 (ja) 2016-12-14
CN103946231B (zh) 2016-10-26
DK2787002T3 (en) 2016-08-29
EP2787002B1 (en) 2016-06-01
EP2787002A4 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
CN103946231A (zh) 齐墩果酸酰胺化衍生物、及其制备方法和应用
CN105418627B (zh) 1‑氧代/酰化‑14‑酰化的冬凌草甲素衍生物、及其制备方法和应用
KR101421140B1 (ko) 메킬리아 락톤 유도체, 그 약제학적 조성물 및 그 제조방법과 용도
CN101323591A (zh) 一类5-位或6-位取代的萘酰亚胺化合物及抗肿瘤应用
CN102127142B (zh) 救必应酸衍生物及其在制备抗肿瘤的药物中的应用
CN108530310A (zh) 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
CN103570738A (zh) 新型青蒿素衍生物及其制法和应用
CN108530444A (zh) 一种新型nampt和ido双重抑制剂及其制备方法和医药用途
CN104119330A (zh) 小檗碱衍生物的合成及其在制备抗肿瘤药物和协同阿霉素抗肿瘤药物组合物中的应用
CN107709335A (zh) Kakeromycin及其衍生物的制造方法
CN102731454A (zh) 去氢木香烃内酯衍生物,其药物组合物及其制备方法和用途
CN106946974B (zh) 一类含吡唑杂环的熊果酰胺衍生物及其合成与应用
CN104039794B (zh) 7‑位取代的汉防己乙素衍生物、及其制备方法和应用
CN108164476B (zh) 间苯二腈类化合物、其应用以及包含该化合物的药物
CN103687859B (zh) 高三尖杉酯碱的胺化衍生物、及其制备方法和应用
CN104334571B (zh) 重楼皂苷i的酰化衍生物、及其制备方法和应用
CN111171018A (zh) 一种查尔酮类化合物及其应用
CN103635476B (zh) 高三尖杉酯碱的酰化衍生物、及其制备方法和应用
CN103946217A (zh) 2-位胺化亚甲基或2-位酯化亚甲基丹参酮衍生物、及其制备方法和应用
CN103958490B (zh) 2-位烷基或芳香基取代的丹参酮衍生物、及其制备方法和应用
CN112778393B (zh) 欧夹竹桃苷衍生物及其制备方法、药物组合物和用途
CN104415033B (zh) 取代唑类化合物作为制备抗肿瘤药物的应用
CN103635475A (zh) 5-位碳取代的汉防己甲素衍生物、及其制备方法和应用
CN103374001B (zh) 咪唑并三嗪类mTOR抑制剂
CN104619324A (zh) ***的组合药物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180510

Address after: Room 102, No. 131, Kai Qing Road, Pudong New Area, Shanghai

Patentee after: Bunsen Pharmaceutical (Shanghai) Co., Ltd.

Address before: 310051 4 4, 6 Jiangling Road, Binjiang District, Hangzhou, Zhejiang.

Patentee before: Hangzhou Bensheng Pharmaceutical Co., Ltd.

TR01 Transfer of patent right